Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
241-260 of 1,738 trials

Urothelial Cancer: BT8009 Treatment Study

We are investigating whether the new drug BT8009, alone or with pembrolizumab, can help patients with advanced urothelial cancer live longer and respond better than standard chemotherapy.

Locally Advanced or Metastatic Urothelial Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

Eosinophilic Granulomatosis With Polyangiitis: NS-229 Study

We are testing a new treatment, NS-229, to see if it helps patients with Eosinophilic Granulomatosis With Polyangiitis achieve remission better than a placebo. The study will also look at any side effects and the time until symptoms worsen.

Eosinophilic Granulomatosis with Polyangiitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Neuroblastoma: ABTL0812 Treatment for Children

We are testing a new drug, ABTL0812, in children with relapsed or refractory neuroblastoma and other solid tumors. The study aims to find the best dose and evaluate its safety and effectiveness when used alone or with other therapies.

Relapsed/Refractory Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: BI 764532 Treatment Study

We are testing different doses of BI 764532 in patients with relapsed small cell lung cancer and other neuroendocrine cancers. The goal is to see if this treatment can help improve outcomes for those who have not responded to prior therapies.

Small Cell Lung CancerNeuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: Rezatapopt Treatment Study

We are evaluating a new treatment for patients with advanced solid tumors that have a specific genetic mutation. The study aims to understand its effectiveness and safety, as well as how it affects quality of life.

Locally Advanced or Metastatic Solid Tumors with TP53 Y220C MutationSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Solid Tumors: [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 Study

We are studying the safety and effectiveness of two new treatments for patients with advanced solid tumors that cannot be removed by surgery. This trial also looks at how well these treatments can help in imaging the tumors.

Colorectal CancerDuctal Adenocarcinoma of PancreasClear Cell Renal Cell Carcinoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Glofitamab for Pediatric B-Cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of glofitamab alone and with other treatments for children and young adults with relapsed or refractory B-cell non-Hodgkin lymphoma. This research aims to find better options for managing this challenging cancer.

B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Elranatamab Treatment Study

We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Montelukast for Mild-Moderate Parkinson’s Disease

We are studying whether Montelukast can slow disease progression in people with mild to moderate Parkinson’s disease. The trial also examines its effects on symptoms and potential side effects.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Pleural Mesothelioma: New Chemotherapy and Immunotherapy Study

We are exploring a new treatment combining chemotherapy and immunotherapy for patients with inoperable pleural mesothelioma. The study will evaluate treatment completion rates, side effects, and overall quality of life.

Inoperable Pleural Mesothelioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Acetic Acid for Healing Skin Ulcers

We are studying whether acetic acid can help improve the healing of skin ulcers with biofilm compared to standard treatment. This trial will look at healing rates and safety over several weeks.

Skin Ulcer>2 yearsEfficacy phase (II)Standard MedicinesDermatology

Advanced MTAP-null Solid Tumors: AMG 193 Treatment Study

We are studying the safety and effectiveness of AMG 193, both alone and with docetaxel, for adults with advanced MTAP-null solid tumors. This research aims to find better treatment options for these patients.

Advanced MTAP-null Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatologyOncology

Retinitis Pigmentosa: New Treatment Trial

We are investigating a new treatment for patients with retinitis pigmentosa. The goal is to see if it can help improve vision or slow down vision loss.

Retinitis PigmentosaSafety phase (I)Efficacy phase (II)Ophthalmology

CMV Prevention in Lung Transplant Recipients: Letermovir Study

We are studying whether letermovir can better prevent CMV infection in lung transplant recipients compared to standard treatment with valganciclovir. This research may help improve care for patients at risk of CMV disease.

Lung Transplant Patients (D+/R-)1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Traumatic Brain Injury: Wharton's Jelly Stem Cells

We are investigating whether stem cells from umbilical cord tissue can help reduce inflammation and improve immune response after a traumatic brain injury. This study aims to find new treatment options for recovery.

Severe Traumatic Brain Injury (TBI)>2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineNeurology

Muscle Invasive Bladder Cancer: New Treatment Combination

We are studying a combination of three medications for patients with muscle invasive bladder cancer who cannot take cisplatin. The goal is to see if this approach can effectively shrink tumors before surgery.

Bladder CancerEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncologyUrology

HER2-Positive Solid Tumors: Disitamab Vedotin Study

We are studying a new treatment called disitamab vedotin for adults with advanced solid tumors that express HER2 and have been previously treated. The trial aims to evaluate its effectiveness and safety.

Ovarian CancerHead and Neck CancerEndometrial Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Metastatic Breast Cancer: Somatostatin Receptor PET Scan Study

We are studying how somatostatin receptors behave in metastatic breast cancer using DOTATOC-68Ga PET scans. This may help us understand the disease better and improve future imaging techniques.

Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

SENS-501 for Children with Hearing Loss from Otoferlin Mutations

We are studying a new injection treatment for children with severe to profound hearing loss due to Otoferlin gene mutations. The trial will assess both the safety and effectiveness of this treatment.

Bilateral Severe to Profound Hearing LossSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOtolaryngology

Acquired Hemophagocytic Syndrome: Ruxolitinib Study

We are studying whether ruxolitinib, combined with standard care, can improve organ function and survival in critically ill patients with acquired hemophagocytic syndrome. This trial also looks at the safety and effects of the drug on various health markers.

Haemophagocytic Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInternal Medicine